<DOC>
	<DOCNO>NCT00201396</DOCNO>
	<brief_summary>Investigate effect induction MEPFL chemotherapy follow concurrent chemoradiotherapy ( CCRT ) disease control survival treatment patient advance NPC .</brief_summary>
	<brief_title>A Multicenter Trial Comparing Induction C/T Followed CCRT v.s . CCRT Alone Stage IV Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Rationale induction chemotherapy : Distant metastasis major cause treatment failure deaths patient loco-regionally advanced NPC . Concurrent chemoradiotherapy may prolong survival patient advance NPC , still flaw high incidence distant metastasis . Induction chemotherapy MEPFL show reduce incidence distant metastasis Phase II study . Induction chemotherapy plus concurrent chemoradiotherapy may improve survival patient advance NPC . Objectives : Investigate effect induction MEPFL chemotherapy follow concurrent chemoradiotherapy ( CCRT ) disease control survival treatment patient advance NPC . Study design : This randomize , multi-center Phase III study . Patients randomize CCRT without MEPFL induction chemotherapy . Type number patient : Patients stage IVA ( T4 ) and/or IVB ( N3 ) without distant metastasis enrol . A total 480 patient randomized detect improvement median overall survival 5.8 8.7 year , a=0.05 power 0.8 use two-sided logrank test one interim analysis . Treatment schedule : Induction chemotherapy CCRT : Arm A : Weekly cisplatin concurrently radiotherapy Arm B : Induction MEPFL three cycle follow weekly cisplatin concurrently radiotherapy . Study endpoint : The primary endpoint disease-free survival calculate duration date randomization date recurrence NPC site include persistent disease +induction chemotherapy/CCRT , death cause ( fail ) , date withdrawal ( last contact date , censor ) , schedule data analysis date ( censor ) . ( revised 8/27/2004 )</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Histologically prove nasopharyngeal carcinoma . T4NxM0 TxN3M0 disease UICC/AJCC 1997 stag system . ( 30 ) Eastern Cooperative Oncology Group performance status &lt; 2 . A leukocyte count ≥3750/mL , Hb ≥ 10 g/dL , platelet count ≥100,000/mL . A serum bilirubin level &lt; 1.5 mg/dL , serum creatinine level &lt; 1.6 mg/dL creatinine clearance &gt; 60 mL/min . Age le 70 year old An informed consent sign . Evidence metastatic disease . Presence another malignancy treat squamous/basal cell carcinoma skin . Presence uncontrolled hypertension , poorly control heart failure . Presence active infection . Patients treat chemotherapy , radiotherapy , immunotherapy , experimental therapy . Women test positive pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>A Multicenter Phase III Trial</keyword>
	<keyword>Induction Chemotherapy</keyword>
	<keyword>Concurrent Chemoradiotherapy</keyword>
	<keyword>Stage IV Nasopharyngeal Carcinoma ( NPC )</keyword>
	<keyword>randomization</keyword>
	<keyword>disease-free survival</keyword>
</DOC>